目的 探討丹紅注射液聯(lián)合依諾肝素鈉注射液治療急性ST段抬高型心肌梗死的臨床療效。方法 選取2015年6月—2016年6月天津中醫(yī)藥大學第一附屬醫(yī)院收治的急性ST段抬高型心肌梗死患者96例為研究對象，所有患者隨機分為對照組和治療組，每組各48例。對照組于溶栓后12 h肌內(nèi)注射依諾肝素鈉注射液，7 500 IU/次，1次/d。治療組在對照組的基礎上靜脈滴注丹紅注射液，30 mL加入到5%葡萄糖注射液250 mL中，1次/d。兩組均連續(xù)治療7 d。觀察兩組的臨床療效，比較兩組的血清學指標和心血管事件發(fā)生情況。結果 治療后，對照組和治療組的總有效率分別為72.9%、91.7%，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。治療后，兩組血清高敏C-反應蛋白（hs-CRP）、肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、肌鈣蛋白T（cTnT）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P < 0.05）；且治療組這些血清學指標明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。對照組和治療組院內(nèi)心血管事件發(fā)生率分別為8.4%、4.2%，院外心血管事件發(fā)生率分別為10.4%、4.2%，兩組比較差異無統(tǒng)計學意義。結論 丹紅注射液聯(lián)合依諾肝素鈉注射液治療急性ST段抬高型心肌梗死具有較好的臨床療效，能降低血清hs-CRP、CK、CK-MB、cTnT水平，安全性較好，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Danhong Injection combined with Enoxaparin Sodium Injection in treatment of acute ST segment elevation myocardial infarction. Methods Patients (96 cases) with acute ST segment elevation myocardial infarction in the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from June 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were im administered with Enoxaparin Sodium Injection after thrombolytic therapy for 12 h, 7 500 IU/time, once daily. Patients in the treatment group were iv administered with Danhong Injection on the basis of the control group, 30 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and serological indexes and cardiovascular event in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.9% and 91.7%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of serum hs-CRP, CK, CK-MB, and cTnT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the hospital cardiovascular event rates in the control and treatment groups were 8.4% and 4.2%, respectively, the outside hospital cardiovascular event rates in the control and treatment groups were 10.4% and 4.2%, respectively, and there was no difference between two groups. Conclusion Danhong Injection combined with Enoxaparin Sodium Injection has clinical curative effect in treatment of acute ST segment elevation myocardial infarction, can decrease the levels of serum hs-CRP, CK, CK-MB, and cTnT, with good safety, which has a certain clinical application value.